You are here: Industry Insights > AstraZeneca

News List

AstraZeneca partners up with CRUK for new UK cancer drug discovery facility pharmafile
December 11, 2018
AstraZeneca is to team up with Cancer Research UK to build a new centre of excellence for accelerating the discovery and development of new cancer drugs, leveraging genetic screening, cancer modelling.
Cancer Research and AstraZeneca launch genomics centre pharmatimes
December 11, 2018
Cancer Research UK and AstraZeneca have announced that they are opening a new centre in Cambridge, UK, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.
AstraZeneca Provides Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in Advanced Head and Neck Cancer americanpharmaceuticalreview
December 10, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised....
AZ’ Imfinzi fails in head and neck cancer trial pharmatimes
December 10, 2018
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
AstraZeneca's head and neck cancer treatment Imfinzi falls flat in Phase III trials pharmafile
December 10, 2018
AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase III EAGLE trial.
AstraZeneca's Calquence found success in lymphoma. Will CLL follow? fiercepharma
December 06, 2018
Just over a year after approval, AstraZenca’s Calquence is giving Johnson & Johnson and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma.
Biocartis, AstraZeneca aim faster lung cancer biomarker results biospectrumasia
December 05, 2018
Many lung cancers are driven by mutations in the epidermal growth factor receptor (EGFR), which occur in 10-15% of NSCLC patients in the US and the EU, and 30-40% of NSCLC patients in Asia.
FDA grants ODD for AstraZeneca’s Fasenra to treat EGPA pharmaceutical-technology
November 29, 2018
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for AstraZeneca’s Fasenra (benralizumab) to treat eosinophilic granulomatosis with polyangiitis (EGPA).....
Trump Medicare Plan Targets Drugs From AstraZeneca to Roche firstwordpharma
November 28, 2018
A proposal from the US Centers for Medicare and Medicaid Services (CMS) could have negative consequences for a wide range of drugmakers, Bloomberg reported Tuesday.
AstraZeneca’s immunotherapy fails in key lung cancer trial pharmaphorum
November 27, 2018
AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck & Co is enjoying huge sales success with Keytruda.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page